The measurement of ligand receptor binding parameters for G-protein-coupled receptors is indispensable in the drug discovery process. Traditional ligand receptor binding assays require scale-up of cells and membrane preparations, which is an expensive and time-consuming process. In this report, the authors describe the development of a homogeneous live-cell binding assay for GPCRs using a fluorophore-labeled nonpeptide ligand. The model assay used Cy3B-labeled telenzepine and Chinese hamster ovary cells expressing M1 muscarinic acetylcholine receptors. This homogeneous live-cell fluorescence binding assay format is superior to the traditional binding methods because it measures binding of a ligand to intact receptors on living cells. The assay requires no washing or separation steps, thereby allowing a real-time kinetic readout for the determination of ligand association and dissociation from the intact receptors. The results also suggest that miniaturization is feasible without compromising the data quality. (Journal of Biomolecular Screening 2008:748-754) 
INTRODUCTION
G -PROTEIN-COUPLED RECEPTORS (GPCRs) are a family of structurally related membrane proteins that control or influence a diverse range of physiological functions and represent the largest family of transmembrane signaling molecules in the human genome. 1 The ligands for GPCRs are a diverse range of hormones, neurotransmitters, autocrine factors, and even photons. The ability to measure and quantify the binding of ligands to these receptors, as well as the resultant responses, has been a key element of the drug discovery process in many disease areas.
The ligand receptor binding assay is one of the most frequently used high-throughput screening (HTS) formats for GPCRs where a ligand is known. In the past, radioligand binding techniques such as filtration or scintillation proximity assay (SPA) have been used in HTS for GPCR targets. The SPA format eliminates the need for filtration and washing steps to separate free ligand from receptor-bound ligand. However, it still relies on the use of a radioisotope and immobilization of the receptor to a solid phase. Technologies developed recently have enabled binding assays to be performed in a nonradioactive assay format. 2, 3 Advances in fluorescent dye chemistry, as well as the introduction of sensitive fluorescence plate readers, allowed ligand receptor binding assays to be performed in a fluorescence polarization assay in a 384-well plate format. 4, 5 The remarkable improvements in fluorescencebased detection using techniques such as the confocal fluorescence correlation spectroscopy (FCS) enabled the development of binding assays at the single-molecule level. 6, 7 These fluorescent technologies allow ligand receptor binding equilibrium to be reached and binding constant determined without separation of the receptor-bound ligand from free ligand.
All of the receptor binding assays mentioned above require solubilized receptors or cell membrane preparations. The cell culture scale-up for membrane preparation is a time-consuming and expensive process. Furthermore, it represents a somewhat artificial system where the cellular components required for the receptor high-affinity state may have been removed during preparation of the membrane fraction. An ideal assay should be simple, performed in 1 step in solution, and be as close as practical to the natural cellular environment. In the past, whole-cell binding assays have been hindered by the need for confocal technology and poor separation of the receptor-bound signal from the background. The fluorometric microvolume assay technology (FMAT) was the first high-throughput platform developed for homogeneous celland bead-based assays, but the 633-nm red laser excitation source limited assays to red dye emissions. [8] [9] [10] Its confocal-based detection limited the scanning throughput for high-density plates. Recently, an innovative approach was developed to determine whole-cell GPCR equilibrium binding and Ca 2+ mobilization using fluorescence ligand and flow cytometry technology. 11 The aim of the present study was to test experimentally whether GPCR binding can be measured in live cells with fluorescencelabeled nonpeptide ligand in a simple no-wash protocol using the novel optics and confined detection region of the IsoCyte™ laser scanning platform in an HTS-compatible format.
MATERIALS AND METHODS

Materials
Cell culture medium Ham's F12 was purchased from Invitrogen Corporation (Carlsbad, CA). Other cell culture reagents, including fetal bovine serum (FBS), penicillin-streptomycin, geneticin (G418), and OptiMEM (without phenol red), were also obtained from Invitrogen Corporation. Tissue culture flasks (225 cm 2 ) and roller bottles (850 cm 2 ) were purchased from Corning, Inc. (Corning, NY). Chinese hamster ovary cell line stably transfected with the human M1 muscarinic acetylcholine receptors (M1R-CHO) was obtained from Euroscreen (Gosselies, Belgium). Black-wall, clear-bottom 96-well tissue culture-treated Packard ViewPlate and Cy3B-telenzepine, a muscarinic acetylcholine receptor antagonist, were obtained from PerkinElmer (Boston, MA). LavaCell stain was obtained from Active Motif (Carlsbad, CA). Chemical compounds used in this study were purchased from Sigma-Aldrich (St. Louis, MO). [ 3 H]-Quinuclidinyl-benzilate ([ 3 H]-QNB), a muscarinic acetylcholine receptor antagonist, was obtained from GE Healthcare (Piscataway, NJ).
M1R-CHO live-cell binding assay
The M1R-CHO cells were maintained in growth medium (Ham's F12, 10% FBS, penicillin-streptomycin 100 units/mL, G418 400 μg/mL, Zeocin 250 μg/mL) at 37 °C in an atmosphere of 5% CO 2 . M1R-CHO cells were seeded at 5000 per well in 100 μL growth medium in 96-well black-wall Packard Viewplates 48 h prior to the experiment and incubated at 37 °C in an atmosphere of 5% CO 2 . The cell binding reaction was performed at room temperature. In brief, the growth medium was removed, and 40 μL of compound, diluted in OptiMEM to concentration needed, was added to the wells followed by the addition of 40 μL of Cy3B-telenzepine diluted in OptiMEM to a final DMSO concentration of 0.5%. The plate was incubated in the dark for 60 to 90 min at room temperature. For kinetic studies, the plate was scanned at various time points after the addition of compound or Cy3B-telenzepine.
The IsoCyte™ laser scanning platform was set up for a single channel of acquisition. Cy3B fluorescence was acquired using a 560-to 610-nm (orange) band pass filter upon 488-nm laser excitation. The image acquisition was done at nominally 5 × 5 μm 2 sampling unless indicated otherwise. The entire 96well plate was scanned with a complete image of each well being acquired and analyzed in a single 4-min scan cycle.
Live-cell staining
LavaCell stains cellular membranes of cells by reacting with free amine groups on proteins. It produces a bright fluorescent signal upon 488-nm laser excitation with peak emission at 610 nm. The LavaCell stain was used at 1.2 μM to label cells after the binding reaction. Briefly, a 2× solution of the LavaCell stain was prepared in OptiMEM, and 80 μL was added to the binding reaction in each well. This resulted in a final volume of 160 μL/well at 1.2 μM LavaCell stain. The plate was incubated in the dark for 30 min at room temperature and then scanned by the IsoCyte™ with fluorescence acquired using a 600 long-pass (red) filter.
M1R membrane filtration binding assay
Human M1R filtration binding assays were performed using [ 3 H]-QNB and cell membranes prepared from M1R-CHO cells. M1R-CHO cells cultured in Corning roller bottles were rinsed with phosphate-buffered saline (PBS) and then incubated with 30 mL of Versene at 37 °C for 10 min. Cells pooled from 4 roller bottles were harvested by centrifugation at 1900 g for 10 min at 4 °C. The cell pellets were washed with ice-cold PBS and frozen at -80 °C until membrane preparation. The cell pellet was suspended in a homogenization buffer (25 mM HEPES [pH 7.4], 10% (w/v) sucrose, and EDTA-free Complete Protease Inhibitor), incubated for 30 min on ice, and homogenized by a glass homogenizer on ice. The cell lysate was centrifuged in a J2-MC centrifuge using a JA10 rotor at 1300 g for 10 min at 4 °C. The supernatant was collected and centrifuged in the Optima Xl-100K centrifuge using the Ti45 rotor at 142,000 g for 60 min at 4 °C to obtain the crude membrane particulate fraction. The particulate fraction was suspended by homogenization in a storage buffer (25 mM HEPES [pH 7.4], 3 mM MgCl 2 , 10% (w/v) sucrose, and EDTA-free Complete Protease Inhibitor). Single-use aliquots were made and flashfrozen in liquid N 2 prior to storage at -80 °C.
Aliquots of M1R-CHO cell membranes suspended in binding buffer (50 mM Tris⋅HCl [pH 7.5], MgCl 2 5 mM, bovine serum albumin [BSA] 0.1%) were incubated with 0.9 nM [ 3 H]-QNB in a final volume of 200 μL in a Costar 96-well polypropylene plate for 90 min at room temperature. Competition binding and IC 50 values of compounds were determined by incubating M1R-CHO cell membranes and [ 3 H]-QNB with various concentrations of compounds. The binding reaction was terminated by rapid filtration through a Unifilter GF/C 96-well filtration plate pretreated with 0.5% polyethyleneimine, then immediately rinsed 6 times with ice-cold Tris⋅HCl buffer (50 mM, pH 7.5). The filter plates were dried in a vacuum oven set at 56 °C. Microscint-20 was added at 40 μL per well, and the plates were sealed. The filter plates were read on a Packard TopCount NXT to determine the radioactive counts. Nonspecific binding was determined in the presence of 10 μM atropine, a nonselective muscarinic acetylcholine receptor antagonist.
Data processing and analysis
The images of each well were processed as follows to determine total, or integrated, cellular fluorescence intensity. A region of interest (ROI) was predefined in the image, and then a threshold was automatically determined based on background levels in the ROI. A "rolling ball" flattening algorithm was employed with a characteristic width of 300 μm. This dimension was chosen so as to be larger than the size of typical cell groupings. The background for each image was determined by analysis of the pixel intensity histogram, and the threshold was set to a constant value above the background level. A known limitation of this approach is that low-intensity cells are undercounted relative to high-intensity cells. An independent measurement of cell locations (e.g., separate stain or laser scatter) can help avoid this and is under investigation. The gray-scale values of all pixels above threshold were summed and background corrected, and this value was taken as the fluorescence intensity (FI) of the ROI. The background was determined as the average of all pixels below threshold.
The result from each well was processed in this manner during acquisition by an integrated image analysis program. Plate results were reported on a well-by-well basis in a text file and imported into Excel (Microsoft, Redmond, WA) for further analysis and processing. Results were expressed as FI or percent of control (POC). IC 50 values were determined by nonlinear regression analysis of the concentration-response curves using Prism (Graphpad Software, San Diego, CA).
RESULTS AND DISCUSSSION
Homogeneous live-cell analysis
A schematic of the IsoCyte™ optical setup that provides highly sensitive detection in homogeneous assay formats is shown in Figure 1 . The intersection of the excitation laser with the collection optical path creates a confined detection region (CDR) that limits collection of the fluorescence to near the bottom of a well. Signals from objects on the bottom of the well, such as adherent cells, are measured with excellent sensitivity due to the use of laser excitation and a high numerical aperture of the collection head. This optical design reduces the background fluorescence and improves the measurement of cellbound signals for ligand receptor binding and antibody-based assays. Although the signal-to-noise (S/N) ratio for individual cells in an image is relatively low (approximately 10-20), the measurement precision is improved by integrating over large number of cells and taking the total FI within a well. The ratio of FI S/N from wells with M1R-CHO cells under the current protocol, as determined by the standard deviation of FI signals from wells with nonspecific binding, is typically >50. The cell density per well had been evaluated, and 5000 cells per well seeded 48 h prior to the experiment appeared to be the optimal condition, as the cell monolayer was below confluent and clusters of cells were separated by sufficient empty space where the background signal could be defined ( Fig. 2A) .
The laser is scanned at a high velocity, making the dwell time within the focal spot approximately 1 μs. This has the advantages of not inducing stress on live cells and not causing photobleaching of fluorophores. Fast laser scanning and fast plate read times provide an additional advantage by reducing the amount of time required outside an incubator if incubation is required for a live-cell assay that performs the best at 37 °C. An individual plate can be removed from an incubator, scanned and analyzed without removing lid, and then returned to the incubator within 5 min.
Cy3B-telenzepine binding kinetics on M1R-CHO cells
An addition of 10 nM Cy3B-telenzepine to M1R-CHO cells induced a time-dependent increase in FI on the monolayer of cells ( Fig. 2A) . In wells where 1 μM atropine was added (nonspecific bound), Cy3B-telenzepine binding to the M1R-CHO cells was completely blocked. Subtraction of FI of the nonspecific bound from the total bound at corresponding time points revealed a binding kinetic for Cy3B-telenzepine to M1R on CHO cells, which reached equilibrium at 90 min (Fig. 2B) . Cell staining using 1. study revealed that cells were present in wells for nonspecific bound, although there was no Cy3B-telenzepine binding. Although only the 10-nM Cy3B-telenzepine results are shown, similar binding kinetics at lower FI was observed in a concentrationdependent manner at 2, 4, 6, and 8 nM Cy3B-telenzepine (data not shown). Figure 3 shows atropine inhibited Cy3B-telenzepine bound to M1R-CHO cells in a concentration-dependent manner. The scanned image from each well of the entire plate was processed using a ROI of 5000, 3800, 2500, or 1250 μm diameter at the center of the well, shown by the white circles in Figure 3A , to generate FI of Cy3B-telenzepine bound to M1R-CHO cells. Figure 3B plots the IC 50 curves of atropine measured by the different ROIs used for analyses. The FI of Cy3B-telenzepine bound to M1R-CHO cells is proportional to the area of the processed image, and the IC 50 curves are parallel. The IC 50 values for ROI 5000, 3800, 2500, and 1250 are 2.9 ± 0.6, 3.1 ± 0.6, 3.2 ± 0.8, and 3.7 ± 1.0 nM, respectively. The results show that the assay is robust and requires only a small number of cells to generate FI data for a dose-response study. This live-cell binding assay can be miniaturized into a 384-well (ROI 2500) or 1536-well (ROI 1250) format without compromising data quality.
Inhibition of Cy3B-telenzepine binding by atropine
In a separate atropine inhibition study, the cells were labeled with a LavaCell stain at the end of the experiment and scanned. The FI of Cy3B-telenzepine bound to M1R-CHO cells was then normalized with FI from the LavaCell staining of the same processed ROI 3800-μm diameter. The atropine concentration-response curve, generated by measuring just the Cy3B-telenzepine bound, overlapped with this LavaCell stain-normalized concentration-response curve and provided identical IC 50 values of 2.3 nM and 2.6 nM, respectively. This result, together with the overlaid images of the Cy3B-telenzepine bound to M1R-CHO and LavaCell staining, suggests that the live-cell fluorescence binding assay produced quality data of Cy3B-telenzepine bound to M1R-CHO cells, and normalization with the LavaCell fluorescence signal can be applied to minimize well-to-well cell density variations within the ROI.
Displacement of bound Cy3B-telenzepine from M1R-CHO cells
The assay protocol was slightly modified to study the kinetics of atropine displacing bound Cy3B-telenzepine from M1R-CHO cells. Cells were incubated with Cy3B-telenzepine for 90 min, and then atropine was added to the cells in various concentrations. The plate was scanned at different time points up to 120 min after the addition of atropine. Figure 4A shows the image of a representative well at 0 or 100 nM atropine at 105 min, in addition to the nonspecific bound control where 1 μM atropine was present from the first addition with Cy3B-telenzepine. LavaCell staining after the time course experiment showed that the cell image in each of the wells matched the Cy3B-telenzepine bound image in each well. When expressing the FI as percent of the control intensity (0 nM of atropine added in the second addition) at each time point, the kinetic data of each atropine concentration tested show a good fit to the singlephase exponential decay model (Fig. 4B) . These results demonstrated that atropine displaced the bound Cy3B-telenzepine from the M1R on CHO cells in a time-and concentrationdependent manner. This is the first reported study of measuring dissociation of telenzepine from the M1R on living cells; telenzepine-M1R bound signal was reduced by 40% in 2 h. In a recent report using a radioligand membrane binding assay, a nonpeptide ligand [ 3 H]-NBI42902 also showed a slow dissociation rate (t 1/2 of 4.3 h) from the human gonadotropin-releasing hormone receptor. 12 This homogeneous live-cell binding assay, which does not require washing or filtration to separate the receptor-bound ligand from free ligand, provides an invaluable tool to study compound-compound interactions at the receptor level as well as ligand receptor association and dissociation measurements. The information provides an opportunity to optimize for kinetic parameters early in the drug discovery process.
Effect of scanning resolution on data quality
A plate from the atropine inhibition study was scanned a second time by a 10 × 10 μm 2 resolution after being scanned at 5 × 5 μm 2 . The 10 × 10 μm 2 scan showed a similar fluorescent image pattern at a lower intensity than 5 × 5 μm 2 (Fig. 5A) . There was no change in the atropine IC 50 value (3.0 nM for 5 × 5 μm 2 compared with 2.9 nM from 10 × 10 μm 2 ). However, when using the 10 × 10 μm 2 resolution, scan time for the entire plate was reduced from 4 to 2 min. The data indicate that scanning at lower resolution increases throughput without compromising data quality. This gain in throughput and identical scanning time required for 384-well and 1536-well plates is an advantage over other similar instruments using confocal technology. 
Comparison of Cy3B-telenzepine live-cell binding to [ 3 H]-QNB membrane binding
The binding profile of a muscarinic receptor agonist (oxotremorine) and 4 antagonists (scopolamine, atropine, telenzepine, and pirenzepine) was determined in the Cy3B-telenzepine live-cell binding assay and compared with the [ 3 H]-QNB membrane filtration binding assay. Notably, the same rank order of potency was observed. The IC 50 values (nM) for scopolamine, atropine, telenzepine, pirenzepine, and oxotremorine were 0.8 ± 0.6, 2.2 ± 0.4, 4.7 ± 2.4, 12.6 ± 1.6, and 2171 ± 1585 when determined by the Cy3B-telenzepine live-cell binding assay (mean ± SD; n = 3) and 0.7 ± 0.1, 2.6 ± 0.2, 7.4 ± 1.5, 60.4 ± 11.3, and 47,500 ± 5000 obtained from the [ 3 H]-QNB membrane filtration binding assay (mean ± SD; n = 4). The antagonist IC 50 values were almost identical in the 2 binding assays, except for pirenzepine, which showed a 5-fold difference. Interestingly, oxotremorine, the muscarinic receptor agonist, was 20-fold more potent in the live-cell binding assay. Because the M1R cell membranes were prepared from the same M1R-CHO cell line used in the live-cell binding assay, it is unlikely that the agonist potency difference observed resulted from different M1R expression levels. One explanation for this difference is that the cellular components, including G-protein and guanosine diphosphate (GDP), that warrant a high-affinity receptor state are intact in the live cell but not in the membrane preparation. The washing and filtration steps required in the membrane filtration binding assay may also introduce assay differences in the binding affinity of the ligand to the receptor. The identical rank order of potency of these compounds in the 2 assays suggests that this live-cell binding assay can substitute the classical radioligand membrane filtration binding assay. This live-cell fluorescence binding assay format is simple and requires a small number of cells compared with the time-consuming steps required to scale up cells and prepare cell membranes for membrane-based binding assays. This assay format provides a flexible cost-saving tool in determining compound-receptor binding affinity. The assay can be performed at any time when the target cell line is in culture and fluorophorelabeled ligand is available.
There is an ongoing discussion regarding the contribution of receptor density and oligomerization for GPCR function. 13 To closely align the data from a binding assay with a cell-based functional assay, one should perform a receptor binding affinity assay and a receptor-activated responsiveness assay simultaneously in the same well. The live-cell binding assay described here may allow the determination of binding affinity of the target GPCR and the receptor-mediated response to be measured from the same cell population in the same well. This would provide a better understanding of the ligand or compound effect on the target GPCR in the context of the cellular physiology and mechanism of action than the traditional way of studying binding affinity and cellular response in separate experiments.
In the past, the synthesis of fluorescent small-molecule ligands encountered difficulty in the retention of the receptor binding profile after the introduction of a bulky fluorophore. Compared with peptide ligands, a potential site for fluorophore conjugation of small-molecule ligands will be in a much closer proximity to the pharmacophore and, as a consequence, is more likely to compromise ligand affinity and efficacy. A common approach to address this issue is to separate the ligand and fluorophore by some form of linker or spacer moiety. Although this has to be tested empirically, many fluorescent nonpeptide ligands have been synthesized and remain active in binding and functional assays. 14 For example, the M1R binding affinity of Cy3B-telenzepine (4.5 nM) used in this study is reduced only by 2.5-fold as compared with the unlabeled telenzepine (1.8 nM) in the [ 3 H]-QNB membrane filtration binding assay. However, receptor internalization can occur through agonist-mediated GPCR endocytosis if the labeled ligand is an agonist. This would have a minimal effect on the fluorescence signal because the IsoCyte™ measures the total FI from the cell monolayer, unless the signal is quenched or the labeled ligand is metabolized inside the cells. Another potential limitation of this technology is the diffusion of the labeled compound into the cells. This phenomenon, which can be validated with confocal microscopy and identified in the competition binding assay, will underestimate the binding affinity, and the compound should not be used as a probe for this live-cell binding assay. The use of these fluorescent tools, coupled with the rapidly advancing complementary imaging technologies, enables one to truly interrogate therapeutically important receptors and their molecular relationship with bioactive ligands at the cellular and subcelluar levels.
In conclusion, we successfully developed a homogeneous fluorescence live-cell binding assay for M1R using an IsoCyte™ laser scanning platform with a simple assay protocol. This assay can determine real-time kinetics of ligand association and dissociation from the intact receptors on cells. The assay can be easily miniaturized into a 1536-well high-density format without compromising data quality.
